Please assess the completion status of the following clinical trial:

Trial Title: Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* being afebrile,~* willing to participate in the trial, and~* the ability to swallow oral medications.~Exclusion Criteria:~* a presence of an acute febrile illness or severe illness that impairs the ability to take oral medication~* HIV-positive child receiving cotrimoxazole prophylaxis,~* a child who has received a dose of antimalarial drug including dihydroartemisinin-piperaquine during the past month; and~* a history of allergy to DHA-PQ.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine will be administered to the intervention arm
- Control (Type: NO_INTERVENTION): Individuals that will get malaria infection and present at the health facility with clinical signs and symptoms will be treated according to the Tanzania National Malaria Treatment guidelines using artemether-lumefantrine.

Based on this trial design, predict the completion outcome and termination type (if applicable).